BCL2 and hematopoietic and lymphoid system neoplasm: In previous studies using cell lines and patient samples derived from diverse blood cancers, we identified loss of the tumour suppressor TP53 as a resistance factor to single agent therapy using either BCL-2-specific or MCL-1-specific BH3-mimetic drugs [24].